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The Search for
Minimal Risk in
International
Paediatric Clinical Trials
Tracy Evans Chan∗
Difficult ethical and regulatory challenges are raised whenever children are
enrolled in non-beneficial research. Their resolution takes on new significance
in the light of transnational pharmaceutical development trials in developing
countries. This paper examines what international guidelines exist and how
they address the challenges posed by involving children in non-beneficial
clinical trials, focussing on the concept of ‘minimal’ risk as a legal and ethical
standard to protect children from exposure to unwarranted risks presented by
such trials. It reviews approaches to the question of minimal risk before
evaluating the adequacy of existing international guidelines to address the needs
of children and what can be done to strengthen them.

I. Introduction
The cornerstone of research ethics involving human subjects in non-beneficial
research is arguably the voluntary informed consent of the human subject.1 While
the principle of beneficence ensures that such research risks are minimised and
appropriate in the light of the benefits to be gained from the knowledge gleaned
from the protocol,2 and that of justice seeks to ensure that the burdens of such
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1.

2.

8

TRIALS OF WAR CRIMINALS BEFORE THE NUREMBERG MILITARY TRIBUNALS UNDER
CONTROL COUNCIL LAW NO. 10, VOL. 2, Nuremberg Code, Guideline 1, at 181-82
(Washington, D.C.: U.S. Government Printing Office, 1949), available at
http://www.nihtraining.com/ohsrsite/guidelines/nuremberg.html [hereinafter Nuremberg
Code].
See, e.g., Council for International Organizations of Medical Sciences, INTERNATIONAL
ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS,
General Ethical Principles (CIOMS, Geneva 2002), available at
http://www.cioms.ch/frame_guidelines_nov_2002.htm [hereinafter CIOMS Guidelines].
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research are fairly distributed amongst the group or community that stands to
benefit from that research,3 ultimately it is the individual, autonomous choice to
align oneself with the researcher’s objectives that legitimates the imposition of the
inevitable risks associated with research participation.4 A duty to contribute to the
biomedical research effort, while often articulated,5 has so far not passed into the
realm of universal or general ethical acceptance.
This autonomy paradigm for non-beneficial research raises serious ethical and
regulatory challenges whenever children (or minors) are enrolled in non-beneficial
research. For empirical and legal reasons, children are considered incapable of
giving the necessary consent to expose themselves to research risk that offers no
direct compensating benefit.6 What is the moral or legal basis, if any at all, for
involving children in such research? What protections and procedures ought to be
put in place should this practice be justified? These issues have long been debated
domestically, with different approaches adopted in various research jurisdictions.7
However, their resolution takes on new significance in the light of international
pharmaceutical development trials. This paper considers what international
guidelines exist and how they address the challenges posed by involving children
in non-beneficial clinical trials, particularly in developing countries. Part II of the
paper describes the globalisation of pharmaceutical trials and the regulatory
challenges vis-à-vis child subjects, while Part III reviews some domestic legal and
ethical approaches to the issue of minimal risk. In the light of this review, Part IV
then evaluates the adequacy of existing international guidelines in addressing the
needs of this vulnerable group of persons, and what needs to be done to strengthen
them.

3.
4.
5.

6.
7.

Id.
Hans Jonas, Philosophical Reflections on Human Experimentation, Daedalus 219, 235-36
(1969).
See, e.g., R. Rhodes, Rethinking Research Ethics, 5(1) Am. J. Bioethics 7, 14-15; D. Brock,
Ethical Issues in Exposing Children to Risks in Research, in CHILDREN AS RESEARCH
SUBJECTS: SCIENCE, ETHICS, AND LAW 90-93 (M. Grodin & L. Glantz eds., 1994) (in
relation to incompetent subjects).
See David N. Weisstub et al., Biomedical Experimentation with Children, in RESEARCH ON
HUMAN SUBJECTS: ETHICS, LAW, AND SOCIAL POLICY 380, 382-84 (David N. Weisstub
ed., 1998).
See infra Part III.

9
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II. The Globalisation of Pharmaceutical Trials and Their Impact
on Children
A. General
The past two decades have seen a noticeable rise in international pharmaceutical
clinical trials in developing countries.8 The reasons for this are both scientific and
pragmatic. If investigational products seek to deal with diseases that are more
common and widespread in developing countries, pharmaceutical companies are
likely to conduct trials in countries where subjects with the relevant medical
condition are to be found and recruited.9 Further, human subjects in developing
countries are less likely to have been exposed to pre-existing pharmaceutical
agents that address the condition under investigation, thus allowing better efficacy
data to be derived.10 More significantly, there are important cost considerations in
‘out-sourcing’ clinical investigations to countries where manpower and recruitment
costs associated with such research are much lower. Pharmaceutical companies
also apparently stand to gain from greatly accelerated trial periods in countries
where ethical and regulatory barriers are lower or non-existent as these countries
may lack similar or basic ethical and regulatory controls as compared to the
sponsoring jurisdiction, often because government officials and medical
professionals lack adequate information and training in evaluating the propriety of
these trials. Finally, there is (at the least) a perception that recruitment in these
developing countries, where potential subjects are far more deferential to medical
professionals and authority figures in general, is much easier.11
B. Children as Therapeutic Orphans
Clinical investigations of pharmaceutical products in children is a scientific
necessity due to the different ranges of diseases in and physiology of children.12
There is currently inadequate paediatric testing of pharmaceutical products,
principally by reason of a lack of adequate economic incentives on the part of
8.

Draft Report of the Joint CIOMS/WHO Working Group, DRUG DEVELOPMENT RESEARCH
(CIOMS, Geneva Dec. 2005) ¶ 1.2 at 7,
http://www.cioms.ch/pv_in_rpc_final_14dec2005.pdf.
Id. ¶ 1.1 at 6.
Ruth Macklin, DOUBLE STANDARDS IN MEDICAL RESEARCH IN DEVELOPING COUNTRIES 7
(2004).
Id. at 7-9.
Ralph E. Kauffman, Scientific Issues in Biomedical Research with Children, in CHILDREN
AS RESEARCH SUBJECTS: SCIENCE, ETHICS, AND LAW, supra note 5, at 29, 34-37.
IN RESOURCE-LIMITED COUNTRIES

9.
10.
11.
12.

10
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pharmaceutical companies, resulting in widespread off-label prescriptions and
interventions for children that are based on inexact extrapolations from the results
of studies in adults.13 This presents an inherent therapeutic risk whenever
pharmaceuticals tested in adult-only clinical trials are used in children. As a matter
of national health policy, some of the leading pharmaceutical development
jurisdictions have gradually begun to work towards adopting overt regulatory or
legislative action to encourage or mandate the inclusion of children in clinical
trials, unless there are specific ethical or scientific reasons to exclude them.14 The
object is to improve the information available on dosage and safety information of
pharmaceutical products for paediatric use. This policy is supported by major
research groups and professional associations.15 The frontrunner of these efforts is
the U.S. Paediatric Research Equity Act of 2003,16 which mandates such paediatric
studies. Apart from legislation being considered in the European Union,17 there is
currently no similar legislation anywhere else in the world. Notwithstanding the
likely greater risks that would be imposed on child subjects as part of this effort,
mandatory testing in children is seen as a better strategy than allowing current offlabel therapeutic practices, which might place even greater risks of harm on
children, to continue.18
C. Regulatory Challenges and the Search for Minimal Risk
The confluence of these two trends suggests that paediatric clinical trials
extending beyond the shores of country sponsoring the research (transnational
trials) are likely to grow. This has been predicted by some commentators,19 and
indeed, domestic paediatric trials in the U.S. have increased since the regulatory
and legislative measures were introduced by the Food and Drug Administration

13.
14.
15.
16.
17.
18.
19.

Carol A. Tauer, Testing Drugs in Pediatric Populations: the FDA Mandate, in 7
ACCOUNTABILITY IN RESEARCH 37, at 39-41 (1999); Patrina H Y Caldwell, Clinical
Trials in Children, 364 LANCET 803 (2004).
Caldwell, supra note 13, at 804-05.
Id.
21 U.S.C.S. § 301 (2006). See Pub. L. No. 108-55, § 1, 2003 U.S.C.C.A.N. (117 Stat
1936). (providing that “[t]his Act may be cited as the 'Pediatric Research Equity Act of
2003.”).
Kathleen R. Gans-Brangs & Paul V. Plourde, The Evolution of Legislation to Regulate
Pediatric Clinical Trials: Present and Continuing Challenges, ADVANCED DRUG
DELIVERY REVIEWS 58 106-15 (2006).
Caldwell, supra note 13, at 806.
Gans-Brangs, supra note 17, at 114.
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(FDA) and Congress respectively.20 What substantive and procedural protections
ought to be in place before such children may be enrolled in clinical trials?
Some international consensus has arguably emerged on the basic ethical
requirements for paediatric clinical trials, as reflected by both domestic state
regulations and guidelines promulgated by international public and professional
organizations. First and foremost, children must be protected from unwarranted
research risk, especially since they are considered a vulnerable group of
individuals who lack adequate autonomy to understand and evaluate research risks
for themselves before enrolment.21 This is seen as a specification of the ethical
principle of respect for persons or beneficence.22 What is not so clear is how this
baseline threshold level of risk, beyond which no child should be exposed to, is to
be defined and applied. A distinction is often drawn between beneficial and nonbeneficial clinical research.23 In respect of the former, the level of acceptable risk
is a function of a balancing of that risk against the prospect of direct benefits
offered by the intervention or pharmaceutical product.24 More controversially,
when it comes to non-beneficial clinical trials, it appears that there is widespread
support for allowing such research that does not offer any direct benefit to the child
subject where the risks imposed are “minimal”25 or “low”,26 although some
jurisdictions are even prepared to go further than this if the countervailing benefits
of the research are sufficiently important enough.27
Second, and arguably as a corollary to this, parental “permission” to enrol the

20.
21.
22.

23.

24.
25.
26.
27.

12

A.J. FLETCHER, PRINCIPLES AND PRACTICE OF PHARMACEUTICAL MEDICINE 183
(Lionel D. Edwards et al. eds., 2002).
CIOMS Guidelines, supra note 2, Guideline 9.
See CIOMS Guidelines, supra note 2; Robert Veatch, Ranking, Balancing, or Simultaneity:
Resolving the Conflict among the Belmont Principles, in BELMONT REVISITED – ETHICAL
PRINCIPLES FOR RESEARCH WITH HUMAN SUBJECTS 196 (James F. Childress et al. eds.,
2005).
Compare United Nations Educational, Scientific and Cultural Organization [UNESCO],
33rd Session of the General Conference of UNESCO, Oct. 19, 2005, Universal Declaration
on Bioethics and Human Rights, ¶ 7(b), available at www.unesco.org and CIOMS
Guidelines, supra note 2, at Guideline 8 and Guideline 9 with ICH Harmonised Tripartite
Guideline, Clinical Investigation of Medicinal Products in the Pediatric Population; E11, ¶
2.6, Current Step 4 version (July 20, 2000), available at www.ich.org.
See World Medical Association, Declaration of Helsinki 2000, ¶ 16, available at
http://www.wma.net/e/ethicsunit/helsinki.htm; CIOMS Guidelines, supra note 2, at
Commentary to Guideline 8.
CIOMS Guidelines, supra note 2, at Guideline 9; UNESCO Declaration, supra note 23, at
art. 7(b).
ICH Harmonised Tripartite Guideline, Guideline for Good Clinical Practice E6(R1) [10
June 1996], para. 4.8.14, available at http://www.ich.org/cache/compo/276-254-1.html.
46 C.F.R. §46.407; see infra Part III.A.3.
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child is necessary.28 “Permission”, rather than “consent”, is used to more
accurately capture the ethical considerations involved in seeking parental approval
before a child is enrolled in a clinical trial or research in general. It is not a matter
of respecting the parent’s autonomy over his individual interests, but rather, at the
least, a respect of the parent’s prima facie authority and responsibility to determine
the proper development and upbringing of the child.29 Furthermore, parental
permission ensures that there is some external evaluation of a research protocol’s
inherent risks, apart from that of the investigator and the institutional review board
(IRB)or ethics committee. Although the latter are better positioned to objectively
evaluate the risks created, parents are arguably in better placed to evaluate the
possible subjective risks (psychological or otherwise) presented in relation to the
particular child.30
Third, the “assent” of the child is required as well.31 “Assent” roughly refers to
the understanding and positive agreement of the child to participate in the trial, at
least to the extent that he or she is capable of and depends on the age, maturity and
psychological development of the particular child.32 This essentially reflects the
importance of respecting the developing autonomy of the child, especially if it is
also desired to educate the child on the importance of becoming a morally
conscious and contributing member of society. Furthermore, respecting the dissent
of the child ensures that undue distress or harm is avoided, particularly when the
research is non-beneficial in nature. Disagreement and uncertainty, however, exist
over what age assent should be required, and if the dissent of a non-competent
child should be respected in every situation.33
Finally, there should be just recruitment criteria and procedures in place to
ensure the fair spreading of the benefit and burdens of such research between
individuals and groups who actually stand to benefit from the knowledge gained
from such research.34 Following from this principle, it is always stipulated that it
28.
29.
30.
31.
32.
33.
34.

See, e.g., CIOMS Guidelines, supra note 2, at Guideline 14; Cf. WMA Helsinki Declaration
2000, supra note 24, at para. 24, which refers to the “informed” consent of a legally
authorised representative of the incompetent subject.
See Leonard H. Glantz, Research with Children, 24 Am. J.L. & Med. 213, at 219-20 (1998).
Weisstub, supra note 6, at 392-94.
CIOMS Guidelines, supra note 2, at Guideline 14: Research involving children; Helsinki
Declaration 2000, supra note 24, at ¶ 25.
CIOMS Guidelines, supra note 2, at Commentary on Guideline 14.
See David Wendler & Seema Shah, Should Children Decide Whether They Are Enrolled in
Nonbeneficial Research, 3(4) Am. J. Bioethics 1 (2003).
CIOMS Guidelines, supra note 2, at Guideline 12: Equitable distribution of burdens and
benefits in the selection of groups of subjects in research.
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must be scientifically necessary to enrol children in the clinical trial in question
because competent adults are unsuitable.35 Further, enrolment should not
unnecessarily target particularly vulnerable sub-groups of children, by reason of
economic, social inequalities or simply because they are more easily accessible by
reason, for example, of their poor health and institutionalization.36
In this paper, I focus on non-beneficial paediatric clinical trials, and in
particular the application of first ethical principle of respect for persons above,
because of the unique difficulties raised whenever incompetent and vulnerable
subjects are sought for a trial or research that does not per se benefit them directly.
The threshold of minimal risk essentially reflects a deontological moral threshold
of risk, based on the respect for the individual child, beyond which it is
impermissible to expose children to no matter what utility or beneficence the
research offers for future child patients or society in general.37 While all the
requirements mentioned above are undoubtedly important, additional social,
cultural and political complications are introduced by international paediatric
clinical trials. The greater likelihood of exploitation of vulnerable populations
(and parents in these communities) in developing countries and the general lack of
adequate regulatory oversight in many developing countries,38 for example, makes
it all the more imperative that children are protected from unnecessary and
unethical exposure to risk in non-beneficial clinical trials.

III. Non-Beneficial Clinical Trials Under
Domestic Legal and Ethical Standards
As a starting point, it is useful to survey what limits are placed on nonbeneficial paediatric clinical trials under domestic law. Standards and procedures
governing research in children take varied forms. There is often a mix of legal and
ethical guidelines, and in federal systems, overlapping and possibly conflicting
federal and state rules.39 What follows is a brief, selective survey of the relevant
rules in the U.S., U.K. and Singapore that serves to highlight the main approaches
taken and difficulties involved.40

35.
36.
37.
38.
39.
40.

14

Id. at Guideline 14 (research involving children).
Id. at Guideline 13 (research involving vulnerable persons).
See Veatch, supra note 22 at 196; L. Kopelman, Minimal Risk as an International Ethical
Standard in Research, 29(3) J. Med. and Philo. 351, 352 (2004) [hereinafter Kopelman,
Int’l Ethical Standard].
See infra Part IV.
See Glantz, supra note 29, at 229-32.
See Kopelman, Int’l Ethical Standard, supra note 37, for a more detailed survey of the
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A. The U.S. Federal Regulations’ Multi-layered Approach
1. Minimal Risk Research
The U.S. Federal Regulations, or Common Rule, represent the most multilayered approach to non-beneficial research involving children. At the baseline,
the Common Rule provides for the commonly adopted “minimal risk” standard for
non-therapeutic paediatric research.41 Minimal risk in the Common Rule means
that the probability and magnitude of harm or discomfort anticipated in the
research are not greater in and of themselves than those encountered in daily life or
during the performance of routine physical or psychological examinations or
tests.42 The ethical justification for such “minimal risk” research is two-fold. It
reflects a shared, communal judgment that the community benefits of such activity
clearly outweigh exposure to a level of risk that is unavoidable and accepted as
part of daily life.43 Therefore, it cannot be said that that child is necessarily made
worse off by participating, if not better off. Further, even if such research may not
offer direct therapeutic benefit, children benefit by participation in a community
practice in which all members have some mutual ties of responsibility to each
other that advances their common interests, and this is also part and parcel of their
socialisation and growth as responsible moral beings.44
The Common Rule offers a dual test for what constitutes this “minimal” risk.
The first limb ambiguously refers to risks encountered in daily life, which could be
interpreted from an objective standpoint as representing some notional common
level of unavoidable risk to which the average child in a community is exposed. It
would therefore reflect an absolute standard. Alternatively, the first limb could be
interpreted as reflecting a subjective level of risk dependent on the daily risks
encountered by the individual paediatric subject in question.45 Fortunately, this
alternative approach seems to be largely rejected in the U.S. on grounds that it
could produce unjust outcomes by placing greater risk on child subjects simply
because social, medical and economic circumstances already expose them higher
levels of risk than more fortunate and privileged children, infringing the justice

41.
42.
43.
44.
45.

‘minimal risk’ standard.
45 C.F.R. § 46.404 (2005). See also 21 C.F.R. § 50.51 (2006) (the equivalent FDA
regulation).
45 C.F.R. § 46.303(d) (2005); 21 C.F.R. § 50.3(k) (2006).
Brock, supra note 5, at 87-88.
Id. at 89-90.
Kopelman, Int’l Ethical Standard, supra note 37, at 361-63.
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principle outlined above.46 A subjective approach would also frustrate the
intended purpose of expediting ethical and regulatory review on the assumption
that the risk exposure of a given clinical trial or research protocol reflects an
objectively minimal level of risk that obviates the necessity for closer scrutiny.47
Unfortunately, even the former absolute everyday risks standard suffers from a
serious shortcoming. It assumes that common every day risks are easily
identifiable, uniform and stable. The U.K. Institute of Medical Ethics examined
this approach in its 1986 report.48 After surveying a wide array of voluntarily
accepted and daily risks for different members of the British population, it
concluded that an everyday standard of risk (that is, risk less than that run in
everyday life) is effectively meaningless since daily life can actually be quite
hazardous in a variable variety of ways, dangerous sport and the like aside.49
Comprehensive empirical data on the range of these types of risk is also lacking,
leaving IRB members to rely on their own subjective perceptions in making risk
assessments.50 Many of these ‘everyday’ risks are also unconsciously accepted or
involuntarily imposed as an adjunct to activities chosen by parents for the social
and educational developmental of the child (e.g. road travel to attend school and
participate in sports, playing on sidewalks or playgrounds close to roads). It does
not follow that the same level of risk is ethically appropriate for intentionally
chosen risk-laden activities like non-beneficial research.51
Some commentators have defended this ‘“everyday risks’” standard on the basis
that it ought only to focus risks that are common to us all (including driving to
work) and is meant to be a qualitative and categorical judgment made by an IRB,
not a quantitative test.52 The problem with the former comment is that activities
common to us all are liable to vary, if not substantially within a community, then
46.

47.
48.
49.
50.
51.
52.

16

See Loretta M. Kopelman, When is Risk Minimal Enough for Children to be Research
Subjects, in CHILDREN AND HEALTH CARE: MORAL AND SOCIAL ISSUES 89, 95
(L. Kopelman & J. Moskop eds., 1989); Robert M. Nelson, Children as Research Subjects,
in BEYOND CONSENT: SEEKING JUSTICE IN RESEARCH 59-60 (Jeffrey P. Kahn et al. eds.,
1998).
Kopelman, Int’l Ethical Standard, supra note 37, at 363.
MEDICAL RESEARCH WITH CHILDREN: ETHICS, LAW AND PRACTICE (Richard H. Nicholson
ed., 1986).
Id. at 84-87.
David Wendler et al., Quantifying the Federal Minimal Risk Standard: Implications for
Pediatric Research Without a Prospect of Direct Benefit, 294(7) J. AM. MED. ASS’N. 826,
827 (2005).
Terrence F. Ackerman, Moral Duties of Parents and Nontherapeutic Clinical Research
Procedures Involving Children, 2(2) BIOETHICS Q. 94, 105-06 (1980).
Benjamin Freedman et al., In Loco Parentis: Minimal Risk as an Ethical Theshold for
Research Upon Children 23(2) HASTINGS CENTER REP. 13, 15-16 (1993).
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most certainly between different geographical and economically under-privileged
communities across the globe. Further, the assumption that IRB members are
likely to apply such a qualitative standard consistently has been proven otherwise.
Various studies have been conducted where researchers and IRB members gave
widely varying responses to what they considered to be minimal risks associated
with invasive and non-invasive research procedures acceptable in research53 and
non-beneficial research specifically.54 In short, perception of risk and its
acceptability depends very much on the individual consulted, and it is reasonable
to expect that IRB members who are personally involved or supportive of research
are likely to be more optimistic about research risk that other professionals and
laypersons.55 This does not bode well for a regulatory standard ultimately meant to
protect the interests of children otherwise dependent on parents who may often
have difficulty understanding the nature of research or the clinical trial in
question.56
This leaves us with the alternative “routine examinations” standard. Susceptible
to the same subjective approach criticisms as the everyday risk standard, an
objective interpretation focussing on routine examinations all healthy people might
ordinarily encounter in the interests of both personal and public health is
preferable.57 Examinations of the latter sort arguably approximate more closely
with the more attenuated notions of benefit presented by clinical trials as compared
with research that offers direct clinical benefit.58 It is also the approach commonly
adopted by various paediatric professional boards making recommendations in
respect of paediatric research.59 However, it must be said that this is a rather
restrictive standard that is likely to rule out most, if not all, non-beneficial clinical
53.
54.
55.
56.

57.
58.
59.

Jeffrey Janofsky & Barbara Starfield, Assessment of Risk in Research on Children, 98 J.
PEDIATRICS 842 (1981).
C. Lenk et al., Non-therapeutic Research With Minors: How Do Chairpersons of German
Research Ethics Committees Decide?, 30 J. Med. Ethics, 85 (2004).
Nicholson, supra note 48, at 104-06.
This is an extrapolation from studies on adults concerning the ‘therapeutic misconception’
in clinical research: see A. CATO ET AL., CLINICAL DRUG TRIALS AND TRIBULATIONS
ch.12, pt. III (2002). See also Michelle Obermann & Joel Frader, Dying Children and
Medical Research: Access to Clinical Trials as Benefit and Burden 29 AM. J. L. & MED.
301, 308-10 (2003).
Kopelman, Int’l Ethical Standard, supra note 37, at 365-67.
Cf. Wendler et al., supra note 50, at 830.
See, e.g., Samuel Gidding, et al., A Policy Regarding Research in Healthy Children, 123 J.
PEDIATRICS 852 (1993); Ethics Advisory Committee, Royal College of Paediatrics and
Child Health, Guidelines for the Ethical Conduct of Medical Research Involving Children,
82 ARCHIVES DISEASE CHILDHOOD 177 (2000).
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trials which necessarily pile on the risks of exposure to the investigational product
over and above any routine medical procedures associated with the trial.60
2. Minor Increase Over Minimal Risk Research
Secondly, the Common Rule allows non-beneficial research involving a ‘minor
increase over minimal risk’ only if, inter alia, the intervention presents experiences
to subjects that are reasonably commensurate with those inherent in their actual or
expected medical, dental, psychological, social or educational situations61 and is
likely to yield generalizable knowledge about the subjects’ disorder or condition
which is of vital importance for the understanding or amelioration of the subjects’
disorder or condition.62 It must be obvious that this provision compounds the
uncertainty by adding another subjective concept of “minor” to the ambiguous
“minimal risk” conception. No guidance is offered as to how one resolves what
amounts to a minor increase over the baseline “minimal risk.”63 One could infer
that the drafters of the rule envisaged that such “minor” increases to the baseline
threshold are justified by the fact that child subjects with the disorder or condition
are likely by reason of their own past experiences to be better able to cope with the
interventions proposed under the trial in question (thus minimising potential
psychological harm) and are more likely than subjects without the relevant
disorder or condition under investigation to potentially benefit at some future point
should therapeutic applications for the disorder or condition materialise sooner.64
An ethical justification offered for this standard seems to be that this higher
level of risk exposure is nonetheless within the realm of legitimate and responsible
parental discretion in allowing children to gain new experiences that may pose
incrementally higher than usual “everyday” risks.65 This moves away from the
strict best interests of the child viewed from an ideal perspective and recognises
that parents are given leeway in exposing children to risk in familial or altruistic
activities that have no ostensible direct and immediate benefit to them apart from
developing their moral character.66 Critics respond that, notwithstanding this
60.
61.
62.
63.
64.
65.
66.

18

Wendler et al., supra note 50, at 830.
45 C.F.R. § 46.406(c) (2005).
45 C.F.R. § 46.406 (2005). See also 21 C.F.R. § 50.53 (2006).
Loretta M. Kopelman, Pediatric Research Regulations Under Legal Scrutiny: Grimes
Narrows Their Interpretation, 30 J. L. MED. & ETHICS 38, 44 (2002).
See David Wendler et al., Non-beneficial Research with Individuals Who Cannot Consent:
Is it Ethically Better to Enrol Healthy or Affected Individuals?, 25(4) IRB: ETHICS &
HUMAN RESEARCH 1, 2 (2003).
Charles Weijer, The Ethical Analysis of Risk, 28 J. L. MED & ETHICS 344, 356 (2000).
Id. See also Lanie Friedman Ross, In Defense of the Hopkins Lead Abatement Studies,
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parental authority, the §46.406 rule as drafted will actually doubly burden sick
children who are more likely to be exposed to increased daily risk simply because
of their existing misfortune, and runs counter to the justice principle. What is
more, clinical trials may also impose uniquely greater risk on sick children for
some types of trials, so the implicit assumption that past experience will tend to
minimise current risks is not invariable.67 They reason that §46.406 should not
categorically be confined to affected children; instead recruitment should first be
determined by a requirement of scientific necessity, which incorporates due
consideration of the particular experiences and special risks of affected children.
That said, the responsible or scrupulous parent standard offers a more
defensible approach to determining acceptable risk thresholds, from both a
normative and practical perspective.68 It seeks to determine “whether the
probability and magnitude of physical and psychological harm is no more than that
to which it is appropriate [for a responsible parent] to intentionally expose a child
for educational purposes in family life situations.”69 This directs the IRB to
compare the risks presented by a clinical trial with those attendant on analogous
decision-making scenarios that parents are presented with in disciplining and
educating their children, thus resonating with an existing socially acceptable risk
threshold in respect of all children in a particular community. The responsible
parent standard also resists a purely quantitative exercise for which empirical data
specific to a community or country may simply be lacking, or the nature of the
risks examined are incommensurable.70 It could actually subsume the basic
§46.404 “minimal risks” rule since ex hypothesi, the responsible parent would not
object to an exposure to minimal risks, provided this is measured by reference to
analogous character-building activity that is intentionally chosen.71 However, as
drafted, §46.406 does not explicitly mandate such an approach.
3. The 407 Approval Process
Finally, the Common Rule envisages exceptional situations where research
offers a reasonable opportunity to further the understanding, prevention or

67.
68.
69.
70.
71.

30 J. LAW MED & ETHICS 50, 54 (2002).
Wendler et al., supra, note 64, at 3.
See Lanie Friedman Ross, Do Healthy Children Deserve Greater Protection In Medical
Research? 142 J. PEDIATRICS 108, 110 (2003); Ackerman, supra note 51, at 106-09.
Ackerman, supra note 51, at 106 (emphasis added).
Freedman et al., supra note 52, at 16-17.
Ross, supra note 68, at 110-11.
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alleviation of a serious problem affecting the health or welfare of the children, and
it will be conducted “in accordance with sound ethical principles”.72 This
provision is interesting at it seems to envision exposure of child subjects to even
greater levels of risk in the cause of the greater good of children, and perhaps even
suggests that it might be possible to perform a utilitarian calculation to justify
significant increases over minimal risk to further the ends stipulated. It is
unsettling that §46.407 does not provide any explicit ethical guidelines particularly
on the threshold protection from research risk. What it does seem to acknowledge
is that we should not rule out the possibility that the importance of the research or
harm is so great that it may occasion a community or societal reconsideration of
the level of risk from which individual children should qualitatively be shielded.
The protections under §46.407 essentially move from the substantive to the
procedural.73 §46.407 provides that such research can only proceed if (a) the
Secretary of the Department of Health and Human Services, (b) in consultation
with a panel of experts in pertinent disciples and (c) following the opportunity for
public review and comment, has determined that the non-beneficial research
(notwithstanding ineligibility under §§46.404 and 46.406) can nonetheless
ethically proceed because envisaged ethical standards may adapt in the light of
unforeseen circumstances. There will doubtless be detractors who argue that nonbeneficial research cannot move beyond the moral compass envisaged by either or
both §§46.404 or 46.406.74
On the whole, the Common Rule provisions on paediatric research reflect two
second-order strategies75 to cope with the inherent ethical difficulties in deciding if
and when children may be enrolled in non-beneficial clinical trials. Although the
more stringent rule-bound approaches under §§46.404 and 46.406 possess serious
conceptual and practical difficulties in their formulation of risk thresholds, they
provide greater controls over what IRBs may approve in respect of children as
compared to §46.407. The latter attempts to compensate for the absence of any
explicit risk threshold by delegating the decision to a more trustworthy decisionmaker coupled with a more publicly transparent decision-making process.

72.
73.
74.
75.
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45 C.F.R. § 46.407 (2005). See also 21 C.F.R. § 50.54 (2006).
See Loretta Kopelman & T. Murphy, Ethical Concerns About Federal Approval of Risky
Pediatric Studies, 113(6) Pediatrics 1783 (2004). See also 21 C.F.R. § 50.54 (2006).
See, e.g., Ackerman, supra note 51, at 108.
Second-order strategies are decisions about the appropriate strategy for reducing the
problems associated with making a first-order decision. See C. Sunstein & E. UllmannMargalit, Second Order Decisions, 110 Ethics 5, 7 (1999).
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B. The Prohibitive Approach
In contrast, it appears that in the United Kingdom, a paediatric clinical trial
must relate “directly to a clinical condition from which the minor suffers or is of
such a nature that it can only be carried out in minors”,76 and “some direct benefit
for the group of patients involved in the clinical trial is to be obtained from that
trial.”77 The first elaborated condition reflects the requirement of scientific
necessity, but also implicitly suggests that healthy children without any medical
condition should not be involved in clinical research. The latter condition is rather
curious since it raises the immediate question of what constitutes group benefit. If
every child in the group must benefit, then would it not have been easier to simply
provide for direct benefit to each trial participant?78 Perhaps what was envisaged
was the possibility of enrolling children with a relevant medical condition in a
randomised controlled trial (RCT). In this scenario, while it is demonstrable that a
majority of child subjects will randomly receive an investigational product that has
some proven efficacy in adults, the control group will not – save perhaps for any
demonstrable placebo effect.79 If this be the case, then the U.K. Regulations
arguably do not provide sufficiently explicit requirements that there must still be
some form of direct medical benefit to every individual child enrolled in the trial,
even though on average there is a direct benefit to the group as a whole. Even if
this were not necessary, there should still be some threshold limit of risk protecting
children in the control group who do not receive the medicinal product under
investigation for the period of the trial. Some other commentators acknowledge
the uncertainty but take a conservative interpretation of the provision to suggest
that it precludes any non-therapeutic research – conferring no personal benefit on
the research participant.80
The position in Singapore is arguably much more explicit. Although
76.
77.
78.

79.
80.

The Medicines for Human Use (Clinical Trials) Regulations 2004, S.I. 1031/2004
[hereinafter U.K. Regulations], Schedule 1, Part 4, Condition 9, available at
www.opsi.gov.uk/si/si2004/20041031.htm.
Id. at Condition 10.
In respect of incapacitated adults, Condition 9 of Part 5 of the U.K. Regulations provides:
“[t]here are grounds for expecting that administering the medicinal product to be tested in
the trial will produce a benefit to the subject outweighing the risks or produce no risk at all”
(emphasis added).
On the placebo effect in pediatric clinical trials, see Franklin Miller et al., When Do The
Federal Regulations Allow Placebo-Controlled Trials in Children?, 142 J. PEDIAT. 102,
105 (2003).
Lynn Hagger & Simon Woods, Children and Research: A Risk of Double Jeopardy?, in
CHILDREN’S HEALTH AND CHILDREN’S RIGHTS 54-55 (Michael Freeman ed., 2006).
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professional guidelines issued by the National Medical Ethics Committee similarly
allow for non-beneficial research in children where the risks are not greater than
those in their “everyday lives” or alternatively interventions that only constitute a
“minor legal assault” like venepuncture.81 In contrast, the Medicines (Clinical
Trials) Regulations 2001 provides that subjects may only be enrolled in a clinical
trial with the appropriate consent.82 Persons who are under 21 years of age may be
enrolled in a clinical trial in three different circumstances. First, if the minor is
married, then the consent of that individual shall suffice to legitimate enrolment in
a clinical trial.83 Second, if the minor and his parent, guardian or legal
representative (“proxy”) both give consent.84 However, in this instance, a minor
can only jointly consent if he has “sufficient understanding” to give such consent –
in short, if he is competent.85 Thirdly, and more pertinently, the proxy’s consent
alone will suffice only if the minor lacks capacity to consent and “there is a
reasonable prospect that participation in the clinical trial will directly benefit that
person”.86 Thus, in the case of a minor who lacks the requisite decision-making
capacity, non-therapeutic trials are simply not permissible.87 The foregoing U.K.
and Singapore provisions arguably reflect a pre-emptive judgment that the risks
associated with non-beneficial clinical trials, the inherent risks presented by the
investigational product, the shortcomings of the review process, the open textured

81.

82.
83.
84.
85.
86.
87.
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National Medical Ethics Committee, Ethical Guidelines on Research Involving Human
Subjects, in NATIONAL MEDICAL ETHICS COMMITTEE, A REVIEW OF ACTIVITIES
(1997)(Sing.), ¶ 2.5.5.1, available at
http://www.moh.gov.sg/corp/publications/details.do?cid=pub_reports&id=13991964.
Medicines (Clinical Trials) Regulations, r. 11 (1978 (amended 1990 and 2000)) (Sing.).
Id. at r.11(1)(a).
Id. at r.11(1)(b).
Id. at r. 11(2)(a).
Id. at r. 11(2)(b) (emphasis added).
This conclusion must be qualified by the provisions of the SINGAPORE GUIDELINE FOR
GOOD CLINICAL PRACTICE [SGGCP], which throws a spanner [wrench] in the works.
SINGAPORE MINISTRY OF HEALTH, SINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE
(1999). Paragraph 4.8.14 of the SGGCP provides that non-therapeutic trials may be
conducted in subjects with consent of a legally acceptable representative if several
conditions are met. These conditions mirror those in para. 4.8.14 of the ICH GCP, infra
note 119. Paragraph 4.8.13 defines a non-therapeutic clinical trial to mean a trial in which
there is no anticipated direct clinical benefit to the subject. These paragraphs are patently
inconsistent with r. 11(2)(b) of the Medicines (Clinical Trials) Regulations discussed in the
main text, at least in so far as paediatric clinical trials are concerned. Paragraph 4.8.14(d) of
the SGGCP also requires that the non-therapeutic trial not be prohibited by law, which
presumably includes subsidiary legislation represented by r. 11(2)(b). I surmise therefore
that Paragraph 4.8.14 of the SGGCP is ineffectual and the full import of r. 11(2)(b) (first
promulgated on 24 March 1978) was not appreciated when the SGGCP, based substantially
on the ICH GCP, was introduced in 1999.
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nature of the “minimal risk” standards available, and even possibly the disparate
impact of parental permission to enrol on children of less-privileged families,88 are
simply too high a price to pay without any compensating direct benefit to the
individual child.
It is obvious from the illustrative survey above that there is no uniform domestic
approach to paediatric risk threshold protection. The threshold of “minimal risk”
is more easily stated than stipulated. Much disagreement and uncertainty exists
over its formulation and adequacy. While the use of some conception of the
“minimal” or “low” risk approach is common, this will likely produce different
results depending on how “everyday” risks are perceived and interpreted by IRB
members. Contrariwise, very strict thresholds also exist that rule out nonbeneficial clinical trials altogether. The literature on the subject, however, reveals
a promising alternative approach based on the exercise a responsible or scrupulous
parent standard. Nevertheless, the U.S. Common Rule is prepared to go even
further by providing for exceptional situations where appropriately transparent and
public processes and more trustworthy institutions are persuaded that the research
imposing greater than minor increases over minimal risk is ethically warranted.

IV. The International Protection of Children in Clinical Trials
A. Helsinki Declaration 2000
What international principles or guidelines are in place to ensure adequate
protection of child subjects, particularly in developing countries that often do not
have adequate regulatory institutions or standards governing clinical research?
There is unfortunately, but not surprisingly, no truly international treaty on the
pharmaceutical testing.89 Paediatric clinical research was only first recognised in

88.

89.

See Ross, supra note 68, at 110 (citing William A. Silverman, The Myth of Informed
Consent in Daily Practice and in Clinical Trials 15 J. MED ETHICS 6 (1989));
S.C. Harth et al., The Psychological Profile of Parents Who Volunteer Their Children for
Clinical Research: A Controlled Study, 18 J. MED. ETHICS 86 (1992); Cf. J.A.F. Zupancic
et al., Determinants of Parental Authorization for Involvement of Newborn Infants in
Clinical Trials, 99 PEDIATRICS 117 (1997).
See, e.g., Dawn Miller, Research and Accountability: The Need for Uniform Regulation of
International Pharmaceutical Drug Testing, 13 PACE INT’L L. REV. 197, 202-11 (2001).
The Convention on Human Rights and Biomedicine, 4 Apr. 1997, Eur. T.S. 164, only binds
Council of Europe signatories: Benjamin Meier, Int’l Protection of Persons Undergoing
Medical Experimentation: Protecting the Right of Informed Consent, 20 BERK. J. INT’L L.
513, 527-29 (2002).
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the World Medical Association’s Declaration of Helsinki 1964, which permitted
proxy consent for all subjects who were legally incompetent in accordance with
national legislation.90 As far as risk assessment and acceptable thresholds are
concerned, rule 16 of Helsinki 2000 provides that “[e]very medical research
project involving human subjects should be preceded by careful assessment of
predictable risks and burdens in comparison with foreseeable benefits to the
subject or to others. This does not preclude the participation of healthy volunteers
in medical research . . . .”91 This rule seems to allow the weighing of third party or
community interests in determining acceptable risk-benefit ratios, suggesting that
these may be weighed in against research risks even though there is no
compensating direct benefit for a child subject. Rule 18 provides that such
research “should only be conducted if the importance of the objective outweighs
the inherent risks and burdens to the subject. This is especially important when the
human subjects are healthy volunteers.”92 Finally, in addition to the recognition of
proxy “informed consent,” rule 24 requires that research for incompetents must be
necessary to promote the health of the population represented and cannot be
performed on legally competent persons, while rule 25 requires the investigator to
obtain the incompetent’s assent where this capability exists.93
The provisions are silent on whether any risk thresholds exist for the
recruitment of incompetent subjects or if any direct benefit is necessary. Much
turns on the unusual concept of “healthy volunteer” in rules 16 and 18 (which is
undefined) since rule 18 recognises that research objectives must be weighed
against risks and burdens to the subject even if no potential benefit to the subject
exists. Thus non-beneficial medical research may enrol such “healthy
volunteers.”94 The entire context suggests two possibilities. “Volunteers” either
refers to subjects without a pre-existing relationship with the medical investigator
(whatever their mental capacity), or only to subjects capable of giving free
individual consent to participate (quite apart from whether they are adequately
informed under rule 22). If the former, then children may be enrolled in nonbeneficial research provided its importance outweighs the risks to the child. The

90.
91.
92.
93.
94.
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World Medical Association 18th General Assembly, Declaration of Helsinki, June 1964, art.
I.11, available at www.cirp.org/library/ethics/helsinki; Cf. Nuremberg Code, supra note 1,
at Guideline 1.
World Medical Association 52nd General Assembly, Declaration of Helsinki, Oct. 2000,
available at: http://www.wma.net/e/policy/b3.htm.
Id. at art. 18.
Id. at art. 24.
Id. at art. 16.
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weight of this overriding research importance is not specified. Otherwise, their
incapacity precludes them from being “volunteers” in non-beneficial research.
Helsinki 2000 is equivocal on this issue.
B. WHO Guidelines 1995
This latter interpretation reflects the approach taken in the World Health
Organization’s Guidelines for Good Clinical Practice (GCP) for Trials on
Pharmaceutical Products (“WHO Guidelines”),95 which have been of significant
influence in the formulation of national good clinical practice guidelines.96
Paragraph 3.3(g) stipulates that consent must always be given by the subject in a
non-therapeutic study, while paragraph 3.3(f) provides that the inclusion of
children in a trial may be acceptable if, inter alia, it is “permitted by local laws and
regulations”, and “the investigator thinks that participation will promote the
welfare and be in the interest of the subject.”97 Taken together, these provisions
appear to preclude child enrolment in non-beneficial research, which cannot be
said to promote the welfare of the child subject instead of merely not being
contrary to his welfare and interests. This prohibitive stance is also reflected in the
recent European Directive on Good Clinical Practice in the Conduct of Clinical
Trials (“EDGCP”).98 Article 4(e) of the EDGCP requires that a clinical trial on
minors can only be undertaken if some direct benefit for the group of patients is
obtained from the clinical trial.99 As discussed above in relation to the similarly
worded U.K. provisions, this at most accepts risk exposure for the control group in
RCT trials, and not non-beneficial trials in general.100

95.

World Health Organization, Guidelines for Good Clinical Practice (GCP) for Trials on
Pharmaceutical Products, WHO Technical Report Series No. 850, Annex 3 (1995),
available at http://www.vghtpe.gov.tw/~mre/goodexp/Fercap-Survey/WHO-GCP1995.pdf.
96. Draft Report of the Joint CIOMS/WHO Working Group, supra note 8 at 30, ¶ 4.5,
lines 29-31.
97. World Health Organization, supra note 95, at ¶ 3.3(f). The agreement of a legally
acceptable representative of this effect should also be recorded by a dated signature.
98. Council Directive 2001/20/EC, 2001 O.J. (L121) 1 (EC), available at
http://eudract.emea.eu.int/docs/Dir2001-20_en.pdf. This presumably overrides the
Convention on Human Rights and Biomedicine, supra note 89, at art. 17(2), which permits
non-beneficial research where, inter alia, it has the aim of contributing to the ultimate
attainment of results capable of conferring benefit on the person concerned, or to other
persons in the same category, and entails only minimal risk and minimal burden for the
individual concerned.
99. Id. at L121/38.
100. See supra Part III.B.
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C. CIOMS Guidelines 2002
A more nuanced interpretation of Helsinki 2000 is embodied in the latest
Council for International Medical Organisations’ International Ethical Guidelines
for Biomedical Research on Human Subjects, 2002 (“CIOMS Guidelines”).101 A
particular objective of these guidelines, developed in collaboration with the WHO,
is to reflect the conditions and needs of “low-resource” countries in applying the
Helsinki Declaration and developing biomedical research policies and ethical
guidelines.102 Notwithstanding the ambiguities in Helsinki 2000, the CIOMS
Guidelines make special provision for research involving children. Guideline 9
specifically provides for limitations in respect of non-beneficial research involving
incompetent individuals:
(1) Research interventions that do not hold out the prospect of direct
benefit for the individual subject should be no more likely and not
greater than risk attached to routine medical or psychological
examinations.
(2) Slight or minor increases above such risk may be permitted when
there is an overriding scientific or medical rationale for such
increases.103
Guideline 9 prudently adopts a routine examinations standard, obviating the
potential for abuse inherent in an “everyday risks” standard that takes advantage of
the heightened health and other risks disadvantaged children in the developing
world are likely to be exposed to in their daily lives.104 There is some doubt as to
whether this routine examinations standard is to be applied subjectively (for the
particular individual) or objectively (those encountered by every healthy
individual). For reasons of fairness in the distribution of research risk mentioned
above, the latter approach is to be preferred.
In respect of the alternative minor increase over minimal risk standard, the
commentary on Guideline 9 closely mirrors the stipulations of the Common Rule
§46.406, but candidly acknowledges that there is no internationally agreed or
precise standard of such an upper threshold of risk for non-beneficial research.105
The suggested solution is that its meaning “is to be inferred from what various

101.
102.
103.
104.
105.
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CIOMS Guidelines, supra note 2.
Id. at Background.
CIOMS Guidelines, supra note 2, at Commentary on Guideline 9.
Id. at para. 2.
Id. at para. 4.
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ethical review committees have reported as having met the standard.”106 This is
problematic since it may devolve a large amount of discretion to a local IRB to
determine what constitutes a “slight” or “minor” increase, which is an inherently
subjective exercise. Given the problems seen in variable determinations of
minimal risk by IRB members in well established research jurisdictions,107 and the
problems of a lack of expertise and independence in developing world regulatory
institutions,108 this is arguably an inappropriate second-order decision making
strategy to adopt. Furthermore, local IRB determinations on acceptable research
risks are rarely made publicly available,109 let alone the detailed reasons for those
determinations. In the absence of any substantive principle or concept grounding
these determinations, and the general lack of comprehensive study and information
on risk profiles,110 there is a real likelihood that such an approach would encourage
information cascades on acceptable risk analogues for non-beneficial clinical trials,
without adequate consideration of the relevant information, ethics and local culture
and circumstances utilised by a “reporting” IRB in coming to its decision.111 This
could have implications both ways, to stifle needed paediatric research or allow
inordinate levels of risk exposure on children in developing countries.
I suggest that a responsible or scrupulous parent standard advocated by
Ackerman and Ross would provide an ethically sounder foundation on which
developing world IRBs could make their deliberations.112 This would direct IRB
members to make qualitative assessments on the socially acceptable levels of
intentionally imposed risk that the host country is prepared to accord parents in the
educational upbringing of their children. In doing so, it mitigates against the
exploitation of differing everyday risk levels across countries by focussing on
analogous voluntary or charitable activities chosen by parents for the moral
education of the child. The legitimate scope of parental duty and prerogative are
arguably questions of universal deliberation and would be a more recognizable

106.
107.
108.
109.

Id. at Commentary on Guideline 9, para. 4.
See supra notes 53 and 54 and accompanying text.
See infra notes 122-124 and accompanying text.
This is the situation in the U.S., where greater transparency is only likely under the §46.407
national review process. However, such 407 reviews are exceptional, see Kopelman &
Murphy, supra note 73, at 1787.
110. Wendler et al., supra note 50, at 827.
111. In an information cascade, people cease relying on their private information or opinions and
decide instead on the basis of signals conveyed by others, see CASS SUNSTEIN, WHY
SOCIETIES NEED DISSENT 55 (2003).
112. Supra notes 51, 68, 70 and accompanying text.
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standard compared to appeals to essentially subjective perceptions of degrees of
risk. Practically speaking, there are concrete examples of appropriate parental
interventions from which an IRB may draw inspiration or which serve as tangible
starting points for risk investigation, such as the discipline of children,
involvement in familial chores and charitable activities. Furthermore, it is a
standard that includes the consideration of subjective harms and developmental
maturity of the particular age group in formulating acceptable risk thresholds.113 In
this vein, a responsible parent standard, having resonance with more commonly
understood conceptions of parental authority in a local setting, would also facilitate
greater public understanding and feedback in the articulation and development of
local analogues of acceptable risks. Finally, it is to be expected that societies and
communities may arrive at differing determinations as to the levels of risk a
responsible parent may permit.114 This accords respect to the varying cultural,
familial and community norms across the globe, rather than ascribe normative
significance to the differing “everyday” risks of life in those communities over
which parents may have little or no choice over.
Nevertheless, it must be acknowledged that differing risk thresholds are prone
to exploitation by investigators impeded by stricter standards in their home
country. Guideline 3 of the CIOMS Guidelines provides a ready solution to this:
An external sponsoring organization and individual investigators should submit the
research protocol for ethical and scientific review in the country of the sponsoring
organization, and the ethical standards applied should be no less stringent than they would
be for research carried out in that country. The health authorities of the host country, as
well as a national or local ethical review committee, should ensure that the proposed
research is responsive to the health needs and priorities of the host country and meets the
115
requisite ethical standards.

In short, there must be dual scientific and ethical review by an IRB in the host
and sponsoring country, with each committee paying particular attention to matters
within their competence.116 This review strategy affords a means of preventing
potentially exploitative trials on children in host countries who are unlikely to

113. See Ackerman, supra note 51, at 107-09.
114. Freedman et al., supra note 52, at 17-18.
115. CIOMS Guidelines, supra note 2, at Guideline 3 (emphasis added). See also
Freedman et al., supra note 52, at 18.
116. The commentary to Guideline 3 also recommends that the host country ethical review
committee must have members or consultants who have a thorough understanding of a
community’s customs and traditions, while Guideline 2 requires the inclusion of a variety of
professional as well as lay persons qualified to represent cultural and moral values of the
community.
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benefit from them. It could be further augmented by requiring host nation IRBs to
provide greater public transparency and participation in evaluating appropriate risk
thresholds given the features of the responsible parent standard discussed above.
No doubt, this will necessarily entail greater cost and delay. However, since the
need to enroll children in non-beneficial trials is widely acknowledged to be
exceptional,117 then this would be a price worth paying.
D. The ICH Good Clinical Practice Guideline 1996
It is unfortunate that the highly influential118 International Conference on the
Harmonization of Technical Requirements for Registration of Pharmaceuticals for
Human Use’s (‘ICH’) Harmonized Tripartite Guideline for Good Clinical Practice
(‘GGCP’)119 provides considerably less clear guidance on non-beneficial trials.
Under the rubric of informed consent, paragraph 4.8.14120 of the GGCP provides
that non-therapeutic trials may be conducted in subjects with the consent of a
legally acceptable representative on the condition that:

117. See, e.g., FLETCHER et al., supra note 20, at 186.; U.S. Federal Drug Administration
Pediatric Advisory Subcommittee, Ethics Working Group Consensus Statement (15 Nov.
1999), ¶ 1, available at http://www.fda.gov/cder/pediatric/ethics-statement.htm.
118. The ICH GCP has been adopted in various non-ICH participating countries in Asia, either
with modifications or a wholesale importation. C.G. Fenn et al., The Contemporary
Situation for the Conduct of Clinical Trials in Asia, 15 INT’L JOURNAL OF
PHARMACEUTICAL MEDICINE 169, 170 (2001). Further, many other countries in the AsiaPacific region are attempting to develop their regulatory systems to be compatible with ICH
guidelines, and various regional harmonization initiatives in Asia Pacific Economic Cooperation, Association of South East Asian Nations, Pan American Health Organisation and
the South African Development Community participating in ICH consultations and
consideration step-wise implementation of ICH guidelines, including the GGCP.
Y. Hayashi, Impact of the Int’l Conference on Harmonisation in Asia, 37 DRUG
INFORMATION JOURNAL 129, 135-36 (2003).
119. ICH Harmonised Tripartite Guideline, supra note 26.
120. The more specific Clinical Investigation of Medicinal Products in the Pediatric Population:
E11 does not provide any elaboration of the requirement of ‘low’ risk under 4.8.14(b),
merely stating that paediatric participants are generally expected to benefit from the clinical
trials. ICH Harmonised Tripartite Guideline, Clinical Investigation of Medicinal Products
in the Pediatric Population; E11, ¶ 2.6, (July 2000), available at
http://www.ich.org/cache/compo/276-254-1.html [hereinafter Clinical Investigation].
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(1) the objectives of the trial cannot be met by means of a trial on subjects who can give
informed consent personally,
(2) the foreseeable risks to the subjects are low;
(3) the negative impact on the subjects well-being is minimised and low;
(4) the trial is not prohibited by law;
(5) the approval of the IRB or IEC is expressly sought and written approval covers this
121
aspect.

Paragraph 4.8.14 suffers from the usual shortcomings entailed in adopting a
relative “low” risk threshold discussed above. It apparently also conflates various
distinct ethical justifications for such research in children and in doing so,
delegates a large amount of discretion on a local IRB without any normative
direction on how it should go about the task. This is understandable in respect of
ICH participating countries who have well developed ethical guidelines, regulatory
mechanisms and expertise in place, but would not be a prudent stance in ensuring
that adequate protections for paediatric subjects are in place for transnational
clinical trials in developing countries. In its report on Clinical Trials in
Developing Countries, the former U.S. National Bioethics Advisory Committee
(“NBAC”) observed that:
the requirement for local review is occasionally tested and sometimes weakened when
research is conducted in developing countries (something that can also happen within U.S.
borders) . . . Although several developing countries have instituted national research ethics
guidelines, and ethics review in some countries is becoming more established, many
difficulties and challenges to local review remain, including lack of experience with and
expertise in ethics review principles and processes; conflict of interest among committee
members; lack of resources for maintaining the committees; length of time it can take to
122
obtain approvals . . . .

Further, while acknowledging that sufficient empirical evidence of the efficacy
of local IRB review is not readily available,123 Macklin draws together sufficient
anecdotal evidence of review lapses in clinical trials conducted in developing
countries that suggest that we cannot assume local review processes have sufficient
expertise and resources to ensure that ethically appropriate risk thresholds are
adhered to, or even that an independent review will always take place in the face of
serious conflicts of interest that exist even amongst these IRBs.124
In the midst of a growing call for greater international harmonisation of clinical

121. Id. at ¶¶ 2.6.3-2.6.5.
122. National Bioethics Advisory Commission, ETHICAL AND POLICY ISSUES IN
INTERNATIONAL RESEARCH: CLINICAL TRIALS IN DEVELOPING COUNTRIES 13 (2001),
available at http://www.georgetown.edu/research/nrcbl/nbac/pubs.html.
123. Macklin, supra note 10, at 159.
124. Id. at 133-58.
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practice standards, it is unfortunate that the more recent ICH Guideline on
Paediatric Clinical Trials has not seen it as necessary to improve on the
requirements of Paragraph 4.8.14 of the ICH GCP, particularly with respect to
clearer substantive risk thresholds and effective review of such non-beneficial
trials.125 This, it is submitted, is a serious lapse. In the midst of a rise in
transnational clinical trials, there may also be a perverse race to the bottom on the
part of developing countries to ensure they possess more facilitative levels of
regulatory requirements, in order to encourage more clinical trials in their countries
and reap their direct and ancillary benefits.126 There is thus no assurance that these
countries will also voluntarily heed the more specific CIOMS Guidelines or more
stringent WHO Guidelines on standards of protection for children. The success of
the first phase of the ICH harmonization initiative, relating to technical
requirements,127 which is strongly supported by the international pharmaceutical
industry,128 suggests that it likely to emerge as the gold standard of not only
technical requirements but also good clinical practices.129 Led by drug
development jurisdictions representing 75% of the global pharmaceutical market
and the pharmaceutical industry,130 the ICH is in the driving seat for setting the
appropriate bar for paediatric subject protections in transnational clinical trials as
pharmaceutical companies would have a strong economic incentive to ensure that
trials adhere to ICH GCP rooted standards in order for product safety and efficacy
data to be accepted in seeking product registration in ICH countries.
For the reasons discussed above, two particular modifications to Paragraph
125. Clinical Investigation, supra note 120.
126. Kevin M. King, A Proposal for the Effective International Recognition of Biomedical
Research Involving Human Subjects, 34 STAN. J. INT’L L. 163, 202 (1998).
127. Draft Report of the Joint CIOMS/WHO Working Group, supra note 8, at 34 ¶ 4.6.
128. C. Nutley argues that industry has three compelling reasons to support ICH and its
harmonization efforts; (a) reduced development times and resources, (b) easier
simultaneous launch of new drugs in many countries and (c) the facilitation of intracompany globalization by the recognition of a common standard. C. NUTLEY, THE VALUE
AND BENEFIT OF ICH TO INDUSTRY (Jan. 2000), http://www.ich.org/cache/compo/276-2541.html (follow “SC Reports and Other Documents” hyperlink)(last visited Dec. 9, 2006).
129. The Joint CIOMS/WHO working group has agreed on the universality of the ICH principles
relating to both scientific and ethical issues and sought to encourage and assist resource
limited countries in their implementation by providing relevant commentaries to the
original ICH text. See draft Report of the Joint CIOMS/WHO Working Group, supra note
8, at 36 ¶ 5.0.
130. Harvey. Bale Jr., M.D., Background and History of the ICH Global Cooperation Group in
ICH, SUMMARY REPORT OF THE 6TH ICH – NEW HORIZONS AND FUTURE CHALLENGES
(Osaka, Japan, 13-15 Nov. 2003) at 32, available at
http://www.ich.org/LOB/media/MEDIA1383.pdf.
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4.8.14 of the ICH GCP are recommended. First, the “low” risk standard should be
replaced by the responsible parent standard to determine acceptable risk levels for
non-beneficial trials. As defined, the CIOMS Guidelines’ routine examinations
standard is likely to rule out non-beneficial clinical trials insofar as they go beyond
routine interventions by exposing subjects to the investigational product.131 Under
the responsible parent standard, this may be permissible even in the absence of
direct clinical benefit, after taking into account the child subject’s prevailing health
risks, past experiences, mental capacity, maturity and the prevailing social norms
in his society or community. Secondly, to counter the problem of possible
exploitation of differing risk thresholds, dual review by sponsoring and host
country IRBs as prescribed by CIOMS Guideline 3 should be implemented under
Paragrah 4.8.14.132
It should be noted that the ICH GCP only lays down the minimum standards for
non-therapeutic paediatric trials. Countries or regions are free to ratchet up
protections by simply prohibiting non-beneficial trials in children, and many have
done so.133 This works against achieving a consistent international approach to the
problem, and may disproportionately expose children in countries with anything
less than an absolute prohibition to the burdens imposed by such trials. Should the
ICH GCP instead simply follow the tack of the WHO Guidelines 1995 and the
EDGCP? Some commentators point out that an absolute prohibition on such
research involvement would be to the long term detriment of children’s health and
well-being.134 If properly applied and reviewed, the responsible parent standard in
fact reflects a stringent objective standard pegged to the overall developmental
welfare of child and thus should ensure their interests are not unfairly
compromised. It also seeks to accommodate the legitimate interests and values of
different societies and communities, faced with their particular paediatric health
challenges, in the search for the appropriate balance between the valid competing
interests of encouraging clinical trials responsive to the health needs of those
children and the respect and protection due to each individual child from research
risks.

131. See G. Koren, Healthy Children as Subjects in Pharmaceutical Research, 24 THEORETICAL
MED. 149, 152 (2003).
132. This is also the position adopted by the recent Universal Declaration on Bioethics and
Human Rights, supra note 23, at art. 21(2).
133. See supra notes 76, 86 and 98.
134. Freedman et al., supra note 52, at 17.
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V. Conclusion
In conclusion, the international guidelines on non-beneficial paediatric trials
differ substantially in approach to the determination of risk thresholds. This is
reflective of the domestic treatment of issue, and the difficult ethical evaluations
involved in balancing therapeutic risks inherent in untested pharmaceuticals and
the imposition of research risks on child subjects. Improvements to the current
difficulties should start at the ICH GCP forum given the influence this conference
has on the general move towards greater international harmonisation on drug
development regulations. Ethically appropriate risk thresholds for non-beneficial
clinical trials should be assessed by a responsible parent standard pegged to the
socially accepted levels of risk exposure associated with the moral and educational
development of children. Enhanced, dual reviews by the sponsoring and host
country IRBs should also be required by the GCP. This would significantly
improve the current voluntary international framework that lacks binding
enforcement mechanisms and perhaps also encourages more focussed empirical
study of comparable familial risk analogues for non-beneficial paediatric clinical
trials in order to improve the ethical assessment of research risk in such clinical
trials.
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